EAN 2026 at a glance
EAN 2026 highlights a competitive shift in neurology toward mechanism-based treatment selection, earlier diagnosis and more precise treatment escalation.** From multiple sclerosis (MS) and generalized myasthenia gravis (gMG) to Alzheimer’s disease and advanced Parkinson’s care, emerging therapies and diagnostic technologies are influencing competitive positioning and clinical decision-making. LucidQuest examines the clinical, commercial and AI-enabled developments that could shape neurology strategies and treatment pathways.
📅 Build your schedule around the topics that matter most.
📥 Download the EAN 2026_Preview_by_LucidQuest
EAN 2026: Key Neurology Developments to Watch
Multiple Sclerosis: BTK Inhibitors Challenge Relapse-Focused Differentiation
BTK inhibitors, including fenebrutinib and tolebrutinib, will test whether slowing disability accumulation can become a credible competitive differentiator beyond relapse control.
The strategic question is whether emerging progression data can establish a meaningful advantage against established disease-modifying therapies, including anti-CD20 treatments, S1P modulators and cladribine.
Generalized Myasthenia Gravis: Immune Mechanisms Reshape Treatment Sequencing
FcRn blockade, C5 inhibition, CD19+ B-cell targeting and BAFF/APRIL inhibition are expanding the range of immune-directed approaches in gMG.
As treatment options evolve, competitive differentiation may increasingly depend on mechanism-based patient selection, sustained disease control and treatment sequencing rather than episodic symptom management alone.
Alzheimer’s Disease: Diagnostic Readiness Becomes a Competitive Advantage
Lecanemab, APOE ε4 stratification, pTau217, blood-based biomarkers and digital cognitive assessment highlight the growing importance of diagnostic infrastructure in Alzheimer’s disease.
Competitive positioning will depend not only on therapeutic efficacy but also on the ability to identify eligible patients, support diagnostic workflows and facilitate timely treatment initiation.
Advanced Parkinson’s Disease: Treatment Escalation Moves Beyond Oral Optimization
Subcutaneous therapies, intestinal gel infusion, apomorphine infusion, adaptive deep brain stimulation (DBS) and focused ultrasound are expanding the range of interventions for advanced Parkinson’s disease.
These approaches raise strategic questions about escalation timing, patient selection, treatment burden and differentiation across device-based and pharmacological options.
Neurology Competitive Landscape: Pharma Strategies and Emerging Therapies at EAN 2026
MS Competition: Sanofi and Roche-Associated Assets Face the Progression Test
MS-focused discussions will bring BTK inhibitor differentiation, disability accumulation, infection risk and comparisons with established disease-modifying therapies into focus.
The competitive question is whether emerging mechanisms can demonstrate sufficiently meaningful clinical benefits to influence treatment selection and market positioning.
gMG Competition: Johnson & Johnson and FcRn-Targeted Strategies
Johnson & Johnson Innovative Medicine and FcRn-focused developments highlight the growing importance of sustained disease control and real-world treatment decisions.
As immune-directed options expand, treatment sequencing, durability and practical differentiation may become increasingly important competitive factors.
Alzheimer’s Competition: Eli Lilly and Roche Face Diagnostic Pathway Challenges
For companies such as Eli Lilly and Roche, Alzheimer’s market positioning may depend as much on diagnostic pathways and treatment capacity as on drug-level efficacy.
Blood-based biomarkers, patient stratification and clinical workflow efficiency could become important factors in translating therapeutic innovation into broader adoption.
Migraine Competition: Lundbeck, Teva and Pfizer Navigate a Crowded Market
Migraine-focused developments involving Lundbeck, Teva Pharmaceuticals and Pfizer highlight competition around preventive treatment thresholds, intervention timing, administration routes and access.
In an increasingly competitive therapeutic landscape, differentiation may depend on aligning treatment choices with patient needs, clinical decision support and practical access considerations.
Artificial Intelligence and Machine Learning at EAN 2026: Digital Biomarkers and Precision Neurology
MS-DETECT: Digital Monitoring Faces the Clinical Validation Test
MS-DETECT and emerging real-world digital biomarkers will examine whether digital monitoring can align sufficiently with established clinical standards to influence MS management.
The key challenge is demonstrating that digital measurements provide reliable, actionable information capable of improving clinical decisions.
AI in Neurology: Predictive Analytics and Digital Decision Support
DaTScan, Remepy and MyClusters-related developments highlight applications of deep learning, mobile biomarkers and headache analytics.
These approaches may support patient segmentation, symptom prediction, wearing-off detection and clinical triage.
Their competitive potential will depend on validation, workflow integration and
Download the EAN 2026 Preview Report
Download LucidQuest’s EAN 2026 preview report for deeper analysis of emerging neurology therapies, competitor positioning and the key competitive developments shaping the neurology landscape.
📅 Build your schedule around the sessions that matter most.
📥 Download the EAN 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
